Cristin-resultat-ID: 844683
Sist endret: 25. oktober 2016, 14:33
NVI-rapporteringsår: 2011
Resultat
Vitenskapelig artikkel
2011

Concomitant use of anti-dementia drugs with psychotropic drugs in Norway-a population-based study

Bidragsytere:
  • Ellen Melbye Langballe
  • Bo Lars Engdahl
  • Geir Selbæk og
  • Hedvig Marie Egeland Nordeng

Tidsskrift

Pharmacoepidemiology and Drug Safety
ISSN 1053-8569
e-ISSN 1099-1557
NVI-nivå 2

Om resultatet

Vitenskapelig artikkel
Publiseringsår: 2011
Volum: 20
Hefte: 12
Sider: 1319 - 1326

Importkilder

Scopus-ID: 2-s2.0-81955162983
Isi-ID: 000297930800013

Beskrivelse Beskrivelse

Tittel

Concomitant use of anti-dementia drugs with psychotropic drugs in Norway-a population-based study

Sammendrag

Purpose Concomitant use of anti-dementia drugs with psychotropic drugs is potentially problematic in patients with dementia. The aim of this study was to investigate how frequently patients in Norway use anti-dementia drugs concomitantly with psychotropic drugs. Methods Analyses are based on data from the Norwegian Prescription Database. All patients who had an anti-dementia drug (ATC-code N06D) dispensed from a Norwegian pharmacy between January 2004 and July 2009 were included. Results A total of 33816 individuals received anti-dementia drugs at some time during this period. The total concomitant use of anti-dementia drugs with psychotropic drugs was 57.4% in men and 65.8% in women. Compared with men, a significantly higher percentage of women used antidepressants (35.8% versus 27.2%), mild hypnotics (28.8% versus 23.6%), benzodiazepines (25.4% versus 20.8%) and opioids (22.8% versus 17.4%) concomitantly with anti-dementia drugs. Concomitant use of antipsychotics with anti-dementia drugs was about 16% for both male and female patients. Of the total sample, 11.9% of the women and 11.7% of the men used acetylcholinesterase inhibitor (AChEI) anti-dementia drugs concomitantly with an interacting psychotropic drug. Conclusion The concomitant use of psychotropic drugs with anti-dementia drugs was extensive, especially among women. Co-medication with potentially interacting drugs occurred at a rate of one in 10. The concomitant use of anti-dementia drugs with psychotropic drugs identified in this study may inform the ongoing clinical debate about drug use in this patient group

Bidragsytere

Ellen Melbye Langballe

  • Tilknyttet:
    Forfatter
    ved Folkehelseinstituttet

Bo Lars Engdahl

  • Tilknyttet:
    Forfatter
    ved Avdeling for kroniske sykdommer og aldring ved Folkehelseinstituttet
Aktiv cristin-person

Geir Selbæk

  • Tilknyttet:
    Forfatter
    ved Aldring og demens, Nasj. Komp.tj. (OUS) ved Oslo universitetssykehus HF
  • Tilknyttet:
    Forfatter
    ved Div Psykisk helsevern ved Sykehuset Innlandet HF
Aktiv cristin-person

Hedvig Marie Egeland Nordeng

  • Tilknyttet:
    Forfatter
    ved Galenisk farmasi og samfunnsfarmasi ved Universitetet i Oslo
  • Tilknyttet:
    Forfatter
    ved Avdeling for barns helse og utvikling ved Folkehelseinstituttet
1 - 4 av 4